• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Media releases
  • PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients

PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients

1 September 2021
Media releases

Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement

PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: CARA) recently received the approval by the U.S. Food and Drug Administration (FDA) for KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. PolyPeptide partnered with Cara Therapeutics for over ten years to develop a peptide-based API as key component of KORSUVA™ and is proud to support Cara Therapeutics going forward with a supply agreement.

Sophie Marechal, PolyPeptide Head of Program Management: “The forthcoming market introduction of KORSUVA™ injection means a substantial improvement in symptoms and meaningful relief for people suffering from severe and debilitating itch. At PolyPeptide we are proud to be part of that process and that our close collaboration with Cara Therapeutics over so many years has now proven to be successful”.

Steve O’Connor, Cara Therapeutics Executive Director, Chemistry Research and CMC: “The FDA approval of KORSUVA™ injection is a milestone for Cara Therapeutics and we are thankful to the team at PolyPeptide for the continued excellent partnership from early stages on. We’re continuing to work together as we prepare the product launch and as we seek further drug approvals in other important markets.”

As part of the supply agreement with Cara Therapeutics, PolyPeptide will manufacture the API in its site in Strasbourg, France, which is one of PolyPeptide’s smaller GMP-certified facilities providing flexible support with a special focus on innovative projects.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

 

 

Download PDF

Back to news

Related posts

9 April 2025

PolyPeptide announces results of the annual General Meeting 2025


Read more
18 March 2025

PolyPeptide publishes invitation to the annual General Meeting 2025


Read more
13 January 2025

Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers